

R&D for Emerging Infectious Diseases

References

Introduction

\$570 billion projected average annual cost of pandemics over coming decades/11,310 lives lost from 2014 West Africa Ebola outbreak: Center for Strategic and International Studies. *Harnessing Multilateral Financing for Health Security Preparedness*. Washington, DC: Center for Strategic and International Studies; 2019.

<https://www.csis.org/analysis/harnessing-multilateral-financing-health-security-preparedness>

3x increase in annual disease outbreaks: Smith K, Golberg, M, Rosenthal S, et al. Global rise in human infectious disease outbreaks. *Journal of the Royal Society*. 2014; 11(101) 1742-5662. <https://doi.org/10.1098/rsif.2014.0950>.

Key missing tools

Crimean-Congo Haemorrhagic fever:

World Health Organization website. Crimean-Congo haemorrhagic fever page. <https://www.who.int/news-room/fact-sheets/detail/crimean-congo-haemorrhagic-fever>. Accessed August 16, 2019.

World Health Organization. *Roadmap for Research and Product Development against Crimean-Congo Haemorrhagic Fever (CCHF)-Draft*. Geneva: World Health Organization; 2018.

<https://www.who.int/blueprint/priority-diseases/key-action/cCHF-draft-r-and-d-roadmap.pdf>.

Clinicaltrials.gov. NCT03020771: Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans.

<https://clinicaltrials.gov/ct2/show/NCT03020771>. Accessed August 16, 2019.

Mazzola L, Cassandra KC. Diagnostic tests for Crimean-Congo haemorrhagic fever: a widespread tickborne disease. *BMJ Global Health*. 2019; 4e001114. <http://dx.doi.org/10.1136/bmjgh-2018-001114>.

Ebola Zaire:

Branswell H. FDA approves an Ebola vaccine, long in development, for the first time. *STAT*. December 19, 2019.

<https://www.statnews.com/2019/12/19/fda-approves-an-ebola-vaccine-long-in-development-for-the-first-time/>

WHO website. Ebola virus disease page. <https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease>. Accessed October 22, 2019.

WHO. *Ebola/Marburg Research and Development (R&D) Roadmap*. Geneva: WHO; 2018.

https://www.who.int/blueprint/priority-diseases/key-action/Ebola-Marburg_Draft_Roadmap_publiccomment_MAY2018.pdf?ua=1.

Branswell, Helen. Ebola vaccine approved in Europe in landmark moment in fight against a deadly disease. *STAT*. November 11, 2019. <https://www.statnews.com/2019/11/11/ebola-vaccine-approved-in-europe-in-landmark-moment-in-fight-against-a-deadly-disease/>.

Second Ebola vaccine to complement “ring vaccination” given green light in DRC [press release]. Geneva, Switzerland: World Health Organization; September 23, 2019. <https://www.who.int/news-room/detail/23-09-2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc>.

McNeil D. A cure for Ebola? Two new treatments prove highly effective in Congo. *The New York Times*. August 12, 2019. <https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html>.

FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens [press release]. Silver Spring, Maryland: US Food and Drug Administration; October 10, 2019. <https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-rapid-diagnostic-test-detecting-ebola-virus-antigens>.

WHO website. Essential medicines and health products: Ebola diagnostics page. https://www.who.int/medicines/ebola-treatment/emp_ebola_diagnostics/en/. Accessed August 16, 2019.

US Food and Drug Administration website. Emergency Use Authorization page. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#ebola>. Accessed October 24, 2019.

Marbug & Ebola Sudan:

WHO website. Marburg virus disease page. <https://www.who.int/en/news-room/fact-sheets/detail/marburg-virus-disease>. Accessed August 16, 2019.

WHO. *Ebola/Marburg Research and Development (R&D) Roadmap*. Geneva: WHO; 2018. https://www.who.int/blueprint/priority-diseases/key-action/Ebola-Marburg_Draft_Roadmap_publiccomment_MAY2018.pdf?ua=1.

WRAIR begins Phase 1 clinical trial of Marburg vaccine [press release]. Silver Spring, Maryland: Military Health System; October 19, 2018. <https://health.mil/News/Articles/2018/10/19/WRAIR-begins-Phase-1-clinical-trial-of-Marburg-vaccine?page=3#pagingAnchor>.

Sabin Vaccine Institute receives \$20.5 million from BARDA with potential of up to \$128 million to develop Ebola Sudan and Marburg Vaccines [press release]. Washington, DC: Sabin Vaccine Institute; October 2, 2019. <https://www.globenewswire.com/news-release/2019/10/01/1923382/0/en/Sabin-Vaccine-Institute-Receives-20-5-Million-From-BARDA-With-Potential-of-up-to-128-Million-to-Develop-Ebola-Sudan-and-Marburg-Vaccines.html>.

BioCryst initiates phase 1 clinical trial of Galidesivir [press release]. Research Triangle Park, North Carolina: BioCryst; January 2, 2019. <http://ir.biocryst.com/news-releases/news-release-details/biocryst-initiates-phase-1-clinical-trial-galidesivir>.

Lassa fever:

World Health Organization website. Lassa fever page. <https://www.who.int/en/news-room/fact-sheets/detail/lassa-fever>. Accessed August 16, 2019.

World Health Organization. *Lassa Fever Research and Development (R&D) Roadmap*. Geneva: World Health Organization; 2018. https://www.who.int/blueprint/priority-diseases/key-action/LassaFever_Draft_Roadmap_publiccomment_MAY2018.pdf?ua=1.

Inovio first to advance Lassa fever candidate vaccine into a clinical trial [press release]. Plymouth Meeting, Pennsylvania and Oslo, Norway: Inovio; May 21, 2019. <http://ir.inovio.com/news-and-media/news/press-release-details/2019/Inovio-First-to-Advance-Lassa-Fever-Candidate-Vaccine-Into-a-Clinical-Trial/default.aspx>.

GeoVax announces upcoming presentation of Lassa fever vaccine data [press release]. Atlanta, Georgia: GeoVax; July 16, 2019. <https://www.globenewswire.com/news-release/2019/07/16/1883361/0/en/GeoVax-Announces-Upcoming-Presentation-of-Lassa-Fever-Vaccine-Data.html>.

Middle East respiratory syndrome coronavirus:

World Health Organization website. Middle East respiratory syndrome coronavirus (MERS-CoV) page. [https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-\(mers-cov\)](https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)). Accessed August 16, 2019.

Modjarrad K, Moorthy V, Embarek P, et al. A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation. *Nature Medicine*. 2016; 22(7):701-5. <https://doi.org/10.1038/nm.4131>.

Modjarrad K. *Research and Development Activities for Middle East Respiratory Syndrome: The Current Landscape*. Geneva: World Health Organization; 2015: <https://www.who.int/blueprint/priority-diseases/key-action/mers-landscape.pdf?ua=1>.

Galford C. Phase 1 first-in-human clinical trial shows promise for MERS CoV vaccine candidate. *Homeland Preparedness News*. July 26, 2019. <https://homelandprepnews.com/stories/35014-phase-1-first-in-human-clinical-trial-shows-promise-for-mers-cov-vaccine-candidate/>.

Cassandra K, Mazzola L, Chua A, et al. An updated roadmap for MERS-CoV research and product development: focus on diagnostics. *BMJ Global Health*. 2019; 4(2): e001105. <https://dx.doi.org/10.1136%2Fbmjgh-2018-001105>.

Nipah:

WHO website. Nipah virus page. <https://www.who.int/news-room/fact-sheets/detail/nipah-virus>. Accessed August 16, 2019.

Denis M. *NIPAH Baseline Situation Analysis – Draft*. Geneva: WHO; 2018. https://www.who.int/blueprint/priority-diseases/key-action/WHO_NIPAH_baseline_situation_analysis_27Jan2018.pdf?ua=1.

WHO. *Nipah Research and Development (R&D) Roadmap*. Geneva: WHO; 2018. https://www.who.int/blueprint/priority-diseases/key-action/Nipah_Draft_Roadmap_publiccomment_MAY2018.pdf?ua=1.

Pacha A. Nipah virus: experimental antiviral drug shows promise. *The Hindu*. June 29, 2019. <https://www.thehindu.com/sci-tech/science/nipah-virus-experimental-antiviral-drug-shows-promise/article28228467.ece>.

Rift Valley fever:

WHO website. Rift Valley fever page. <https://www.who.int/news-room/fact-sheets/detail/rift-valley-fever>. Accessed August 16, 2019.

Wyckoff J. Colorado State University receives \$9.5M to develop Rift Valley fever vaccine. *Healio Infectious Disease News*. July 22, 2019. <https://www.healio.com/infectious-disease/vaccine-preventable-diseases/news/online/%7Bb2508152-67f9-4dec-b3bf-ceed43314a45%7D/colorado-state-university-receives-95m-to-develop-rift-valley-fever-vaccine>.

Zika:

WHO. *Current Zika Product Pipeline*. Geneva: WHO; 2016. <https://www.who.int/blueprint/priority-diseases/key-action/zika-rd-pipeline.pdf?ua=1>.

WHO website. WHO vaccine pipeline tracker page. https://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/. Accessed August 16, 2019.

US Food and Drug Administration website. Emergency Use Authorization page. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#ebola>. Accessed October 24, 2019.

Pandemic influenza:

Taylor A. first universal flu vaccine to enter phase 3 trial. *The Scientist*. November 12, 2018. <https://www.the-scientist.com/news-opinion/first-universal-flu-vaccine-to-enter-phase-3-trial-65073>.

U.S. Department of Health and Human Services. *Pandemic Influenza Plan: 2017 Update*. Washington, DC: U.S. Department of Health and Human Services; 2017. <https://www.cdc.gov/flu/pandemic-resources/pdf/pan-flu-report-2017v2.pdf>.

Research Progress

Ebola vaccine:

Branswell H. FDA approves an Ebola vaccine, long in development, for the first time. *STAT*. December 19, 2019. <https://www.statnews.com/2019/12/19/fda-approves-an-ebola-vaccine-long-in-development-for-the-first-time/>

Branswell, Helen. Ebola vaccine approved in Europe in landmark moment in fight against a deadly disease. *STAT*. November 11, 2019. <https://www.statnews.com/2019/11/11/ebola-vaccine-approved-in-europe-in-landmark-moment-in-fight-against-a-deadly-disease/?>.

Ebola vaccine more than 97% effective in DRC outbreak. *Healio Infectious Disease News*. April 15, 2019. <https://www.healio.com/infectious-disease/emerging-diseases/news/online/%7B595b1729-f589-4a9a-8aef-ef4b4b05866b%7D/ebola-vaccine-more-than-97-effective-in-drc-outbreak>.

Second Ebola vaccine to complement “ring vaccination” given green light in DRC [press release]. Geneva, Switzerland: WHO; September 23, 2019. <https://www.who.int/news-room/detail/23-09-2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc>.

National Institute of Allergy and Infectious Diseases website. Ebola vaccines page. <https://www.niaid.nih.gov/diseases-conditions/ebola-vaccines>. Accessed August 16, 2019.

HHS accelerates development of first Ebola vaccines and drugs [press release]. Washington, DC: Department of Health and Human Services; September 29, 2017. <https://www.hhs.gov/about/news/2017/09/29/hhs-accelerates-development-first-ebola-vaccines-and-drugs.html>.

U.S. Department of Defense website. DoD Helps Fight Ebola in Liberia and West Africa page. https://archive.defense.gov/home/features/2014/1014_ebola/. Accessed August 16, 2019.

Experimental Ebola treatments: A cure for Ebola? Two new treatments prove highly effective in Congo. *The New York Times*. August 12, 2019. <https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html>.

Vaccine for Marburg:

WRAIR begins phase 1 clinical trial of Marburg vaccine [press release]. Silver Spring, Maryland: Military Health System; October 19, 2018. <https://health.mil/News/Articles/2018/10/19/WRAIR-begins-Phase-1-clinical-trial-of-Marburg-vaccine?page=3#pagingAnchor>.

Sabin Vaccine institute receives \$20.5 million from BARDA with potential of up to \$128 million to develop Ebola Sudan and Marburg vaccines [press release]. Washington, DC: Sabin Vaccine Institute; October 2, 2019. <https://www.globenewswire.com/news-release/2019/10/01/1923382/0/en/Sabin-Vaccine-Institute-Receives-20-5-Million-From-BARDA-With-Potential-of-up-to-128-Million-to-Develop-Ebola-Sudan-and-Marburg-Vaccines.html>.

Vaccine for Middle East respiratory syndrome coronavirus: Galford C. Phase 1 first-in-human clinical trial shows promise for MERS CoV vaccine candidate. *Homeland Preparedness News*. July 26, 2019. <https://homelandprepnews.com/stories/35014-phase-1-first-in-human-clinical-trial-shows-promise-for-mers-cov-vaccine-candidate/>

Universal flu vaccine: First universal flu vaccine to enter phase 3 trial. *The Scientist*. November 12, 2018. <https://www.the-scientist.com/news-opinion/first-universal-flu-vaccine-to-enter-phase-3-trial-65073>.

Dozen Zika vaccine candidates: WHO website. WHO vaccine pipeline tracker page. https://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/. Accessed August 16, 2019.

Diagnostic tools for EIDs:

FDA allows marketing of first rapid diagnostic test for detecting Ebola virus antigens [press release]. Silver Spring, Maryland: US Food and Drug Administration. October 10, 2019. <https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-first-rapid-diagnostic-test-detecting-ebola-virus-antigens>.

US Food and Drug Administration website. Emergency Use Authorization page. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#ebola>. Accessed August 16, 2019.

Global Funding for R&D for World Health Organization Blueprint Priority EIDs, 2017

Data from forthcoming report from Policy Cures Research assessing global investment in R&D for EIDs identified in the World Health Organization's R&D Blueprint.

US government R&D efforts

Office of the Assistant Secretary for Preparedness and Response website. Biomedical Advanced Research and Development Authority page. <https://www.phe.gov/about/barda/Pages/default.aspx>. Accessed August 16, 2019.

National Institute of Allergy and Infectious Diseases website. Biodefense and emerging infectious diseases page. <https://www.niaid.nih.gov/research/biodefense-emerging-infectious-diseases>. Accessed August 16, 2019.

Cullison T, Morrison JS. *The U.S. Department of Defense's Role in Health Security: Current Capabilities and Recommendations for the Future*. Washington, DC: Center for Strategic and International Studies; 2019. https://csis-prod.s3.amazonaws.com/s3fs-public/publication/190701_CullisonMorrison_DoDHealthSecurity_WEB_v2.pdf.

7 ways CDC is keeping us safe from deadly diseases [blog post]. Washington, DC: Global Health Technologies Coalition; August 27, 2017. <https://www.ghcoalition.org/blog/7-ways-cdc-is-keeping-us-safe-from-deadly-diseases>.

Fighting Ebola: A Grand Challenge for Development website. <http://www.ebolagrandchallenge.net/>. Accessed August 16, 2019.

Combating Zika and Future Threats: A Grand Challenge for Development website. <https://www.usaid.gov/grandchallenges/zika>. Accessed August 16, 2019.

US Food & Drug Administration website. Tropical disease priority review voucher program page. <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program>. Accessed October 23, 2019.

US Food and Drug Administration website. Emergency Use Authorization page. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#ebola>. Accessed August 16, 2019.